MDxHealth (NASDAQ:MDXH) Stock Rating Lowered by William Blair

Posted by on May 16th, 2026

MDxHealth (NASDAQ:MDXH – Get Free Report) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a research report issued on Thursday, MarketBeat reports.

Several other analysts have also commented on the stock. BTIG Research lowered their price objective on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $4.63.

Read Our Latest Research Report on MDXH

MDxHealth Stock Performance

Shares of MDXH stock opened at $0.89 on Thursday. The firm has a market cap of $44.20 million, a price-to-earnings ratio of -1.37 and a beta of 1.60. MDxHealth has a 52 week low of $0.68 and a 52 week high of $5.33. The firm’s 50-day simple moving average is $2.42 and its two-hundred day simple moving average is $3.23.

MDxHealth (NASDAQ:MDXH – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $23.90 million during the quarter, compared to the consensus estimate of $30.89 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 29.90%. Analysts forecast that MDxHealth will post -0.41 earnings per share for the current year.

Institutional Trading of MDxHealth

Several hedge funds and other institutional investors have recently modified their holdings of the business. Perkins Capital Management Inc. raised its position in shares of MDxHealth by 7.1% in the first quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after purchasing an additional 97,500 shares during the period. Kennedy Capital Management LLC bought a new stake in shares of MDxHealth in the third quarter valued at approximately $1,826,000. FreeGulliver LLC raised its position in shares of MDxHealth by 25.7% in the fourth quarter. FreeGulliver LLC now owns 317,894 shares of the company’s stock valued at $1,135,000 after purchasing an additional 65,000 shares during the period. Renaissance Technologies LLC raised its position in shares of MDxHealth by 21.8% in the first quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock valued at $701,000 after purchasing an additional 54,600 shares during the period. Finally, Mink Brook Asset Management LLC raised its position in shares of MDxHealth by 64.9% in the fourth quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock valued at $940,000 after purchasing an additional 103,686 shares during the period.

MDxHealth Company Profile

(Get Free Report)

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.

Read More

Analyst Recommendations for MDxHealth (NASDAQ:MDXH)

Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.